Prostate Cancer

Lutetium-177 rosopatamab tetraxetan demonstrated an acceptable safety and tolerability profile with no new safety signals in patients with PSMA-positive mCRPC.

Results from the AMPLIFY trial are intended to support an FDA submission seeking approval of 64Cu-SAR-bisPSMA as a diagnostic imaging agent for BCR of prostate cancer.

According to Lantheus, Pylarify TruVu is formulated to improve product stability at higher radioactive concentrations, facilitating more efficient manufacturing and distribution.

“Biochemical responses were seen at all dose levels, with an overall PSA50 response of 62% and a PSA90 response of 40%," according to Fred Saad, CQ, MD, FRCS, FCAHS.

Karim Fizazi, MD, PhD, reported that the 9-year prostate cancer-specific survival rate was 90% (95% CI, 86-94) in patients receiving cabazitaxel vs 89% (95% CI, 84-93) in patients not receiving cabazitaxel.

"Capivasertib in combination with abiraterone represents a potential first-in-class targeted treatment for patients with this now PTEN-defined metastatic APMN,” said Daniel J. George, MD.

Enrique Gallardo, MD, discusses the final overall survival (OS) results from the EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in patients with metastatic castration-resistant prostate cancer.

"Enzalutamide plus radium-223 is an option in first-line treatment for mCRPC patients with bone metastases," said Enrique Gallardo, MD.

Median OS was 28 months (95% CI, 13-NR) in arm 1, 37 months (95% CI, 26-NR) in arm 2, and 68 months (95% CI, 38-NR) in arm 3.

Austin Kirschner, MD, PhD, discusses the recent US commercial launch of the PROSTOX Standard test and its potential to inform radiation treatment decisions for patients with prostate cancer.

PROSTOX Standard estimates the risk of late genitourinary toxicity following conventionally fractionated or moderately hypofractionated radiation therapy for localized prostate cancer.

Bourlon outlines what to watch for in prostate, urothelial, kidney, and testicular cancer.

Across 7 randomized trials, 177Lu-PSMA-617 significantly prolonged progression-free survival vs standard therapies, with no significant difference in adverse events.

Despite early termination of the trial, its results provide scientific rationale for further investigation into targeting alternative AR domains in mHSPC.

A newly published meta-analysis found that adding metastasis-directed therapy to standard of care was associated with extended progression-free survival in oligometastatic prostate cancer, without adding significant safety risks.

The phase 2 Alliance A222001 trial demonstrated that oxybutynin led to clinically meaningful improvements in hot flash frequency and quality of life among men receiving hormone therapy for prostate cancer.

The following FAQs highlight key guideline recommendations relevant to clinicians regarding the early detection of prostate cancer.

URO-1’s FDA-cleared SUREcore and coreCARE prostate biopsy devices have been adopted at multiple Novant Health hospitals as part of a systemwide value analysis.

A recap of the FDA submissions and regulatory decisions in urology from January 2026.

ANDROMEDA is looking to build on previous findings from the LUNAR trial in recurrent, oligometastatic prostate cancer.

Cooled laser focal therapy with the ProFocal Device showed promising cancer control in patients with localized prostate cancer.

Regarding acceptable risk thresholds, Alam describes himself as relatively risk-averse, favoring a 5% to 10% miss rate for Grade Group 2 or higher disease when considering biopsy avoidance.